Nezih PİŞKİNPAŞA, YAŞAR SERTBAŞ, Emin PİŞKİNPAŞA

Pegile interferon alfa-2a ve ribavirin ile kronik C hepatiti tedavisi sırasında akut miyokard infarktüsü gelişen hasta: Bir olgu sunumu

Kronik C hepatitinin pegile interferon alfa-2a ve ribavirin ile tedavi edi- limesi sırasında akut miyokard infarktüsü gelişen 60 yaşındaki bir erkek hastayı sunuyoruz. Hasta, tedaviye başlandıktan iki ay sonra akut an - terior miyokard infarktüsü geçirdi.Tedavinin bir ay öncesinde yapılan kardiyolojik tetkiklerde iskemik kalp hastalığı tespit edilememişti. Akut miyokard infarktüsünün ciddi bir yan etki olduğunu düşündük.

A patient who developed acute myocardial infarction during pegylated interferon alpha-2a and ribavirin therapy for chronic hepatitis C: A case report

We present the case of a 60-year-old male patient who developed acute myocardial infarction while undergoing pegylated interferon al- pha-2a and ribavirin therapy for chronic C hepatitis. After two months of therapy, the patient experienced acute anterior myocardial infarc - tion. No ischemic heart disease was diagnosed by cardiologic examina - tions one month before the initiation of the therapy. We believe his acute myocardial infarction was a serious side effect.

PDF

___

1. Ökten A, Demir K, Kaymakoğlu S, et al. Kronik hepatitlerin etyolojik dağılımı. Turk J Gastroenterol 1998; 2: 113-5.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975-82.
3. Di Bisceglia AM, McHUtchison J, Rice CM. New therapeutic strate - gies for hepatitis C. Hepatology 2002; 35: 224-31.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized study. Lancet 2001; 358: 958-65.
5. Fried MW. Side effects of therapy of hepatitis C and their manage - ment. Hepatology 2002; 36: 237-44.
6. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 57-65.
7. Kumar V, Cotran SR, Robbins SL.Temel Patoloji. In.:Çevikbaş U, ed. 6 th ed. İstanbul. Nobel Tıp Kitapevi 2000; 283-9.
8. Pocok SJ, Shaper G, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglyserides and total cholestherol in isch- aemic heart disease. Br Med J 1989:298:998-1002.
9. Graystone JT, Kuo CC, Wang SP, et al.A new chlamydia psittaci strein, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
10. Teragawa H, Hondo T, Amano H, et al. Adverse effects of interfer- on on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37: 905-15.
11. Rechcinski T, Matusik D, Rudzinski D, et al. Exacerbation of atrio- ventricular block during treatment of hepatitis C with peginterfer- on. Polskie Archiwum Medycyny Wewnetrznej 2007; 1: 1-3.
12. Hoofnagle JH, Seff LB. Peginterferon and chronic hepatitis C. N Engl J Med 2006;355:2444-51.
13. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 3: 557-61.
14. Forde KA, Haynes K, Troxel AB, et al. Risk of myocardial infarction associated with chronic hepatitis C virus infection. J Viral Hepat 2012;19:271-7.